title: [Quality assurance in head and neck medical oncology].
abstract: In medical oncology, how can we be sure that the right drug is being administered to the right patient at the right time? The implementation of quality assurance criteria is important in medical oncology, in order to ensure that the patient receives the best treatment safely. There is very little literature about quality assurance in medical oncology, as opposed to radiotherapy or cancer surgery. Quality assurance must cover the entire patient care process, from the diagnosis, to the therapeutic decision and drug distribution, including its selection, its preparation and its delivery to the patient (administration and dosage), and finally the potential side effects and their management. The dose-intensity respect is crucial, and its reduction can negatively affect overall survival rates, as shown in breast and testis cancers for example. In head and neck medical oncology, it is essential to respect the few well-standardized recommendations and the dose-intensity, in a population with numerous comorbidities. We will first review quality assurance criteria for the general medical oncology organization and then focus on head and neck medical oncology. We will then describe administration specificities of head and neck treatments (chemoradiation, radiation plus cetuximab, postoperative chemoradiation, induction and palliative chemotherapy) as well as their follow-up. Lastly, we will offer some recommendations to improve quality assurance in head and neck medical oncology.
authors.affiliation: CHU Saint-André, Service d'oncologie médicale, 1, rue Jean-Burguet, 33075 Bordeaux cedex, France.
authors.forename: Laurence
authors.initials: L
authors.lastname: Digue
authors.affiliation: CHU Saint-André, Service de pharmacie, 1, rue Jean-Burguet, 33075 Bordeaux cedex, France.
authors.forename: Stéphane
authors.initials: S
authors.lastname: Pedeboscq
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage; D000970:Antineoplastic Agents / Q000008:administration & dosage; D000068818:Cetuximab; D059248:Chemoradiotherapy / Q000379:methods / Q000592:standards; D017024:Chemotherapy, Adjuvant / Q000379:methods / Q000592:standards; D005602:France; D006258:Head and Neck Neoplasms / Q000628:therapy*; D006801:Humans; D008495:Medical Oncology / Q000592:standards*; D010166:Palliative Care / Q000592:standards; D011785:Quality Assurance, Health Care; D011786:Quality Control
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000068818:Cetuximab
keywords: chemotherapy; head and neck squamous cell carcinomas; medical oncology; quality assurance; targeted therapy